Form 4: EyePoint Pharmaceuticals Director Acquires Shares Through RSU Vesting

EyePoint Pharmaceuticals Director Nancy Lurker acquired 11,111 shares of common stock on July 10, 2025, through the vesting of restricted stock units, increasing her direct beneficial ownership.

Summary

• Nancy Lurker, a Director of EyePoint Pharmaceuticals, Inc. (EYPT), acquired 11,111 shares of common stock.
• The acquisition occurred on July 10, 2025, through the vesting of restricted stock units (RSUs).
• The transaction price for the acquired shares was $0.00, indicating a non-cash acquisition from RSU vesting.
• Following this transaction, Nancy Lurker directly beneficially owns 216,547 shares of EyePoint Pharmaceuticals common stock.
• Additionally, 126,889 shares are indirectly beneficially owned through a Family Trust, for which beneficial ownership is disclaimed by the reporting person.
• The restricted stock units from which these shares vested began vesting in three ratable annual installments starting July 10, 2024.

Sentiment

Score: 7

Explanation: The transaction reflects a routine vesting of equity compensation for a director, increasing their direct ownership and aligning interests with shareholders.

Positives

• A Director, Nancy Lurker, increased her direct beneficial ownership in EyePoint Pharmaceuticals, Inc. by 11,111 shares.
• The acquisition of shares through RSU vesting aligns management's interests with shareholders.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• Indirect beneficial ownership of 126,889 shares is held by a Family Trust for the benefit of the reporting person's children, with the reporting person's spouse as trustee. The reporting person disclaims beneficial ownership of these shares.

Stakeholder Impact

• Shareholders: Increased alignment of a director's interests with shareholders due to increased direct equity ownership.
• Management: The transaction is part of the director's compensation structure, reinforcing their commitment to the company.

Next Steps

• Future vesting installments of restricted stock units are expected to occur annually based on the original vesting schedule.

Key Dates

Recommendation

Keywords

EyePoint Pharmaceuticals, EYPT, Form 4, Insider Transaction, Stock Acquisition, Restricted Stock Units, RSU Vesting, Director, Nancy Lurker, SEC Filing